BGM
MPLT

Burkehill Global Management’s MapLight Therapeutics MPLT Stock Holding History

Burkehill Global Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.52M Hold
75,000
– – 0.08% 142
2025
Q4 		$1.32M Buy
+75,000
New +$1.26M 0.09% 138

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Burkehill Global Management's MPLT Position: Q1 2026 in Review

Burkehill Global Management held its MapLight Therapeutics (MPLT) position steady in Q1 2026 at 75,000 shares worth $1.52M. The position accounts for 0.08% of the portfolio, ranked #142.

Burkehill Global Management first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Burkehill Global Management held 75,000 shares of MapLight Therapeutics worth $1.52M as of Q1 2026.
  • Burkehill Global Management left its MapLight Therapeutics share count unchanged in Q1 2026.
  • MapLight Therapeutics made up 0.08% of Burkehill Global Management's portfolio in Q1 2026, its #142 holding.
  • Burkehill Global Management first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.